Annual CFF
$10.04 M
-$76.06 M-88.34%
December 31, 2024
Summary
- As of March 13, 2025, ALT annual cash flow from financing activities is $10.04 million, with the most recent change of -$76.06 million (-88.34%) on December 31, 2024.
- During the last 3 years, ALT annual CFF has fallen by -$55.05 million (-84.57%).
- ALT annual CFF is now -95.30% below its all-time high of $213.49 million, reached on December 31, 2020.
Performance
ALT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$10.09 M
+$9.82 M+3691.35%
December 1, 2024
Summary
- As of March 13, 2025, ALT quarterly cash flow from financing activities is $10.09 million, with the most recent change of +$9.82 million (+3691.35%) on December 1, 2024.
- Over the past year, ALT quarterly CFF has dropped by -$62.67 million (-86.14%).
- ALT quarterly CFF is now -92.59% below its all-time high of $136.15 million, reached on September 30, 2020.
Performance
ALT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$10.04 M
-$62.67 M-86.19%
December 1, 2024
Summary
- As of March 13, 2025, ALT TTM cash flow from financing activities is $10.04 million, with the most recent change of -$62.67 million (-86.19%) on December 1, 2024.
- Over the past year, ALT TTM CFF has dropped by -$76.06 million (-88.34%).
- ALT TTM CFF is now -95.95% below its all-time high of $247.81 million, reached on March 31, 2021.
Performance
ALT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ALT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -88.3% | -86.1% | -88.3% |
| 3 y3 years | -84.6% | -19.6% | -84.6% |
| 5 y5 years | -19.9% | +10000.0% | -19.9% |
ALT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -88.3% | at low | -86.1% | +3439.4% | -88.3% | at low |
| 5 y | 5-year | -95.3% | at low | -92.6% | +3439.4% | -96.0% | >+9999.0% |
| alltime | all time | -95.3% | +4402.0% | -92.6% | +391.5% | -96.0% | +413.3% |
Altimmune Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $10.04 M(-88.3%) | - | - |
| Dec 2024 | - | $10.09 M(+3691.4%) | $10.04 M(-86.2%) |
| Sep 2024 | - | $266.00 K(-678.3%) | $72.71 M(-0.4%) |
| Jun 2024 | - | -$46.00 K(-82.4%) | $73.03 M(-15.2%) |
| Mar 2024 | - | -$261.00 K(-100.4%) | $86.15 M(+0.0%) |
| Dec 2023 | $86.11 M(+51.6%) | $72.75 M(>+9900.0%) | $86.11 M(+547.0%) |
| Sep 2023 | - | $588.00 K(-95.5%) | $13.31 M(-70.3%) |
| Jun 2023 | - | $13.06 M(-4426.2%) | $44.78 M(-16.0%) |
| Mar 2023 | - | -$302.00 K(+602.3%) | $53.30 M(-6.1%) |
| Dec 2022 | $56.78 M(-12.8%) | -$43.00 K(-100.1%) | $56.78 M(-18.1%) |
| Sep 2022 | - | $32.06 M(+48.5%) | $69.36 M(+85.3%) |
| Jun 2022 | - | $21.58 M(+578.5%) | $37.42 M(+10.5%) |
| Mar 2022 | - | $3.18 M(-74.6%) | $33.86 M(-48.0%) |
| Dec 2021 | $65.10 M(-69.5%) | $12.54 M(>+9900.0%) | $65.10 M(-13.5%) |
| Sep 2021 | - | $125.00 K(-99.3%) | $75.27 M(-64.4%) |
| Jun 2021 | - | $18.02 M(-47.6%) | $211.29 M(-14.7%) |
| Mar 2021 | - | $34.42 M(+51.6%) | $247.81 M(+16.1%) |
| Dec 2020 | $213.49 M(+1603.5%) | $22.70 M(-83.3%) | $213.49 M(+11.9%) |
| Sep 2020 | - | $136.15 M(+149.6%) | $190.83 M(+249.3%) |
| Jun 2020 | - | $54.54 M(>+9900.0%) | $54.63 M(<-9900.0%) |
| Mar 2020 | - | $96.70 K(+115.4%) | -$70.30 K(-100.6%) |
| Dec 2019 | $12.53 M(-61.4%) | $44.90 K(-180.5%) | $12.53 M(-71.5%) |
| Sep 2019 | - | -$55.80 K(-64.3%) | $44.01 M(-9.2%) |
| Jun 2019 | - | -$156.10 K(-101.2%) | $48.47 M(+7.3%) |
| Mar 2019 | - | $12.70 M(-59.7%) | $45.17 M(+39.0%) |
| Dec 2018 | $32.49 M(+105.1%) | $31.52 M(+614.3%) | $32.49 M(+3244.3%) |
| Sep 2018 | - | $4.41 M(-227.5%) | $971.50 K(-89.8%) |
| Jun 2018 | - | -$3.46 M(<-9900.0%) | $9.55 M(-25.4%) |
| Mar 2018 | - | $18.50 K(>+9900.0%) | $12.81 M(-19.2%) |
| Dec 2017 | $15.84 M(+217.9%) | $0.00(-100.0%) | $15.84 M(+4.6%) |
| Sep 2017 | - | $12.99 M(-6568.1%) | $15.15 M(+258.9%) |
| Jun 2017 | - | -$200.80 K(-106.6%) | $4.22 M(-47.3%) |
| Mar 2017 | - | $3.05 M(-541.4%) | $8.01 M(+60.8%) |
| Dec 2016 | $4.98 M(+2133.3%) | -$691.90 K(-133.6%) | $4.98 M(-12.6%) |
| Sep 2016 | - | $2.06 M(-42.7%) | $5.70 M(+44.0%) |
| Jun 2016 | - | $3.59 M(>+9900.0%) | $3.96 M(+863.6%) |
| Mar 2016 | - | $22.40 K(-24.1%) | $411.10 K(+84.3%) |
| Dec 2015 | $223.10 K | $29.50 K(-90.7%) | $223.00 K(-91.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | $317.00 K(+651.2%) | $2.74 M(-78.8%) |
| Jun 2015 | - | $42.20 K(-125.5%) | $12.93 M(-14.9%) |
| Mar 2015 | - | -$165.70 K(-106.5%) | $15.19 M(-9.2%) |
| Dec 2014 | $16.73 M(+232.7%) | $2.55 M(-75.7%) | $16.73 M(+11.7%) |
| Sep 2014 | - | $10.50 M(+355.2%) | $14.97 M(+181.7%) |
| Jun 2014 | - | $2.31 M(+67.4%) | $5.32 M(-17.8%) |
| Mar 2014 | - | $1.38 M(+74.0%) | $6.47 M(+28.6%) |
| Dec 2013 | $5.03 M(+35.2%) | $791.70 K(-5.8%) | $5.03 M(+15.4%) |
| Sep 2013 | - | $840.30 K(-75.7%) | $4.36 M(-7.8%) |
| Jun 2013 | - | $3.46 M(-5825.8%) | $4.73 M(+939.2%) |
| Mar 2013 | - | -$60.40 K(-149.5%) | $455.00 K(-87.8%) |
| Dec 2012 | $3.72 M(-35.7%) | $122.10 K(-89.9%) | $3.72 M(+2.5%) |
| Sep 2012 | - | $1.21 M(-248.3%) | $3.63 M(+52.9%) |
| Jun 2012 | - | -$815.10 K(-125.4%) | $2.37 M(-73.6%) |
| Mar 2012 | - | $3.20 M(>+9900.0%) | $8.97 M(+55.2%) |
| Dec 2011 | $5.78 M(-73.1%) | $31.10 K(-164.9%) | $5.78 M(-73.3%) |
| Sep 2011 | - | -$47.90 K(-100.8%) | $21.63 M(-14.0%) |
| Jun 2011 | - | $5.79 M(>+9900.0%) | $25.15 M(+16.4%) |
| Mar 2011 | - | $12.80 K(-99.9%) | $21.60 M(+0.6%) |
| Dec 2010 | $21.46 M(+14.2%) | $15.88 M(+357.3%) | $21.46 M(+274.1%) |
| Sep 2010 | - | $3.47 M(+55.4%) | $5.74 M(-7.9%) |
| Jun 2010 | - | $2.24 M(-1885.2%) | $6.23 M(-40.3%) |
| Mar 2010 | - | -$125.20 K(-181.5%) | $10.44 M(-44.5%) |
| Dec 2009 | $18.79 M(+679.5%) | $153.70 K(-96.1%) | $18.79 M(-22.5%) |
| Sep 2009 | - | $3.96 M(-38.5%) | $24.25 M(+27.1%) |
| Jun 2009 | - | $6.45 M(-21.7%) | $19.08 M(+64.0%) |
| Mar 2009 | - | $8.23 M(+46.5%) | $11.64 M(+382.9%) |
| Dec 2008 | $2.41 M(-96.1%) | $5.62 M(-565.6%) | $2.41 M(-175.2%) |
| Sep 2008 | - | -$1.21 M(+20.6%) | -$3.21 M(+60.3%) |
| Jun 2008 | - | -$1.00 M(0.0%) | -$2.00 M(+100.0%) |
| Mar 2008 | - | -$1.00 M(-111.1%) | -$1.00 M(-104.9%) |
| Dec 2007 | $61.93 M(+442.0%) | - | - |
| Mar 2007 | - | $9.02 M(+1071.4%) | $20.44 M(+78.9%) |
| Dec 2006 | $11.43 M(-83.6%) | $769.60 K(-92.8%) | $11.43 M(+7.2%) |
| Sep 2006 | - | $10.66 M(>+9900.0%) | $10.66 M(>+9900.0%) |
| Jun 2006 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2006 | - | $0.00 | $0.00 |
| Dec 2005 | $69.48 M | - | - |
FAQ
- What is Altimmune annual cash flow from financing activities?
- What is the all time high annual CFF for Altimmune?
- What is Altimmune annual CFF year-on-year change?
- What is Altimmune quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Altimmune?
- What is Altimmune quarterly CFF year-on-year change?
- What is Altimmune TTM cash flow from financing activities?
- What is the all time high TTM CFF for Altimmune?
- What is Altimmune TTM CFF year-on-year change?
What is Altimmune annual cash flow from financing activities?
The current annual CFF of ALT is $10.04 M
What is the all time high annual CFF for Altimmune?
Altimmune all-time high annual cash flow from financing activities is $213.49 M
What is Altimmune annual CFF year-on-year change?
Over the past year, ALT annual cash flow from financing activities has changed by -$76.06 M (-88.34%)
What is Altimmune quarterly cash flow from financing activities?
The current quarterly CFF of ALT is $10.09 M
What is the all time high quarterly CFF for Altimmune?
Altimmune all-time high quarterly cash flow from financing activities is $136.15 M
What is Altimmune quarterly CFF year-on-year change?
Over the past year, ALT quarterly cash flow from financing activities has changed by -$62.67 M (-86.14%)
What is Altimmune TTM cash flow from financing activities?
The current TTM CFF of ALT is $10.04 M
What is the all time high TTM CFF for Altimmune?
Altimmune all-time high TTM cash flow from financing activities is $247.81 M
What is Altimmune TTM CFF year-on-year change?
Over the past year, ALT TTM cash flow from financing activities has changed by -$76.06 M (-88.34%)